Search criteria | ||||
Análisis de la implementación de los Informes de Posicionamiento Terapéutico en España | ||||
Míriam Solozabal, Laura Planellas, Elisabet Viayna, Neus Canal | ||||
Health Economics & Outcomes Research. Real-World Insights. IQVIA España | ||||
Revista Española de Economía de la Salud. 2019; 14(3):596-605 |
||||
, Article | ||||
, Spain | ||||
Abstract: https://www.economiadelasalud.com/Articulo.aspx?i=v14n3d018 | ||||
Condition | Year | Language | Analysis type | |
, Health policy, Pricing and reimbursement, Public Health | 2019 | Spanish | , Clinical setting: hospital, Clinical setting: Primary care, Internet or Interactive voice response system, Pricing & Reimbursement, Public Health | |
WHAT INTERPRETATION OF ICERS IN ORPHAN DISEASES? A FRENCH EXAMPLE. | ||||
Moutier Hélène; Bourguignon Sandrine; Maurel Frédérique; Bodaghi Charles | ||||
RWI IQVIA France | ||||
ISPOR 2018 |
||||
, Poster | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Health economics, Pricing and reimbursement, Rare Diseases | 2018 | English | , Cost effectiveness, Pricing & Reimbursement, Willingness to pay | |
Overview of German AMNOG Dossiers with Price Analysis Before and After Early Benefit Assessment | ||||
Tremmel M, Batscheider A, Bocuk D, Roxlau T, Antoni B, Elena Mihaylova, Bonduelle D | ||||
IQVIA Commercial GmbH & Co. OHG, Munich, Germany IQVIA RDS Bulgaria EOOD, Sofia, Bulgaria | ||||
, Abstract | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Health policy, Pricing and reimbursement | 2018 | English | , Pricing & Reimbursement, Review | |
The Impact of Label Extensions on the Reimbursed Price of Pharmaceutical Products Assessed According to §35A SGB V in Germany Oncological and Metabolic Diseases | ||||
Schmalhofer C, Eheberg D, Tremmel M, Bocuk D, Roxlau T, Antoni B, Bonduelle D | ||||
IQVIA Commercial GmbH & Co. OHG, Munich, Germany | ||||
, Abstract | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Health policy, Metabolic Disorders , Oncology, Pricing and reimbursement | 2018 | English | , Cost analysis, Pricing & Reimbursement | |
Healthcare Resource Utilization and Costs among Psoriasis Patients Treated with Biologics, Overall and by Disease Severity | ||||
Murage MJ, Anderson A, Oliveria SA, Casso D, Ojeh CK, Muram TM, Merola JF, Araujo AB | ||||
Murage MJ: Eli Lilly and Company; Anderson A: IQVIA; Oliveria SA: IQVIA; Casso D: IQVIA; Ojeh CK: Eli Lilly and Company; Muram TM: Eli Lilly and Company; Merola JF: Harvard Medical School; Araujo AB: Eli Lilly and Company | ||||
Journal of Medical Economics |
||||
, Article | ||||
, USA | ||||
Abstract: https://doi.org/10.1080/13696998.2018.1472097 | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Patient Registries & Real-World Study Methods, Pricing and reimbursement | 2018 | English | , Cost analysis, Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis | |
Valoración de la innovación, ¿es “el innovómetro” una herramienta útil y su clasificación reproducible? | ||||
Otermin A, Callejo D, Gasche D, Viayna E, Rubio M, Sumalla M, Solozabal M. | ||||
HEOR-RWI, IQVIA | ||||
XXXVIII Jornadas de Economía de la Salud, Gran Canaria 2018 |
||||
, Poster | ||||
, Spain | ||||
Abstract: http://www.aes.es/jornadas/es/ | ||||
Condition | Year | Language | Analysis type | |
, Health policy, Pricing and reimbursement | 2018 | Spanish | , Pricing & Reimbursement | |
How a new innovation assessment tool relates to recent drug launches for Spanish National acess | ||||
Míriam Solozabal, Elisabet Viayna, Marta Rubio, Mireia Sumalla, Ane Otermin, David Gasche, Laura Planellas, Daniel Callejo | ||||
HEOR-RWI, IQVIA Spain | ||||
ISPOR Europe 2018. 10-14 November 2018 | Barcelona, Spain |
||||
, Poster | ||||
, Spain | ||||
Abstract: https://www.iqvia.com/-/media/iqvia/pdfs/isporbarcelona2018posters/november-13/how-a-new-innovation-assessment-tool-relates-to-recent-drug-launches-for-spanish-national-access.pdf?la=en&hash=1D16D1D70ADE257D3A09480F1B1EEB002BDE83A4 | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2018 | English | , Clinical setting: hospital, Pricing & Reimbursement | |
The impact of biosimilar launch on molecule price and pharmaceutical expense: the case of the insulin glargine in Italy | ||||
Tucci C1, Cioni L1, Mantuano M1, Tettamanti A1 | ||||
1 QuintilesIMS, Milan, Italy | ||||
ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland |
||||
, Poster | ||||
, Italy | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health policy, Pricing and reimbursement, Regulatory | 2017 | English | , Literature Review, Pricing & Reimbursement, Public Health | |
Drug commercialization before the pricing and reimbursement in Italy: the non negotiated C Class (C-nn) | ||||
Mantuano M1, Cioni L1 | ||||
1 QuintilesIMS, Milan, Italy | ||||
ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland |
||||
, Poster | ||||
, Italy | ||||
Condition | Year | Language | Analysis type | |
, Health policy, Pricing and reimbursement, Regulatory | 2017 | English | , Literature Review, Pricing & Reimbursement, Public Health | |
Análisis de coste-efectividad de empagliflozina en pacientes con diabetes mellitus tipo 2 y enfermedad cardiovascular establecida en España [Analysis of cost-effectiveness of empagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease established in Spain]. | ||||
Barrull C1, Massafrets M2, Planellas L1, Perulero N1 | ||||
1 RWI, QuintilesIMS, Barcelona 2 Market Access Department, Boehringer Ingelheim, Barcelona | ||||
XXXVII Jornadas de Economía de la Salud2017, 6 - 8 de septiembre, Barcelona, España |
||||
, Poster | ||||
, Spain | ||||
Abstract: http://www.aes.es/jornadas/en/ | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Diabetes, Health economics, Pricing and reimbursement | 2017 | Spanish | , Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Cost effectiveness, Cost utility, Literature Review, Patient questionnaire, Randomised controlled trial | |
Regional market access pathways for diagnostics in Italy. | ||||
Mantuano M1, Dionisi M2, Paolini D2, Gancitano G2, Urbinati D1 | ||||
1 IMS Health, Milan, Italy 2 Roche Diagnostics, Italy. | ||||
ISPOR 19th Annual European Congress, 2016, 29 October-2 November, Vienna, Austria. |
||||
, Poster | ||||
, Italy | ||||
Condition | Year | Language | Analysis type | |
, Health policy, Pricing and reimbursement, Regulatory | 2016 | English | , Review | |
IMPACT OF POST-INSCRIPTION STUDIES ON REASSESSMENT IN FRANCE: A CASE STUDY ON ORPHAN DRUGS | ||||
Jubert H, Ouali I, Kolahi C | ||||
IMS Health France | ||||
19th ISPOR congress 2016 |
||||
, Abstract, Poster | ||||
, France | ||||
Abstract: https://www.ispor.org/research_pdfs/54/pdffiles/PHP311.pdf | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2016 | English | , Clinical setting: Primary care, Literature Review, Pricing & Reimbursement, Review | |
COSTS EVOLUTION OF CANCER THERAPIES IN EUROPE FROM 2004 TO 2014 | ||||
Tetafort A, Aubert JM, Perrot D, Brigot G, Kolahi C, Ansolabehere X | ||||
IMS Health France | ||||
19th ISPOR Congress 2016 |
||||
, Abstract, Poster | ||||
, France, Germany, Italy, UK | ||||
Abstract: https://www.ispor.org/research_pdfs/54/pdffiles/PCN82.pdf | ||||
Condition | Year | Language | Analysis type | |
, Oncology, Pricing and reimbursement | 2016 | English | , Clinical setting: hospital, Cost analysis, Pricing & Reimbursement, Retrospective database analysis | |
Quantification of patient preference analysis_Wearing the federal joint committee lens to assess evidence | ||||
Gaba D1, Eheberg D, Bonduelle D | ||||
1 Quintiles IMS, Gurgaon, India 2 QuintilesIMS, Munich, Germany | ||||
, Poster | ||||
, Germany, India | ||||
Condition | Year | Language | Analysis type | |
, Health status & patient reported outcomes, Pricing and reimbursement | 2016 | English | , Pricing & Reimbursement | |
Best supportive care or therapy according to physicians choice as appropriate comparator for german HTA dossiers-an underestimated chance or risk for the benefit assessment | ||||
Bonduelle D1, Eheberg D1, Jakovac M1, Dannemann S1 | ||||
1 QuintilesIMS, Munich, Germany | ||||
, Poster | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2016 | English | , Pricing & Reimbursement | |
pCPA/CDR/pCODR Changes and Impact to Market Access in Canada | ||||
Millson B, Zhang Y | ||||
IMS Brogan, A unit of IMS Health, Kirkland, QC, Canada | ||||
2016 ISPOR Conference |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/hta-ispor-poster-2016.pdf | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2016 | English | , Database Study | |
From centralized marketing authorization to national reimbursement - a challenging journey for new medical products with placebo controlled trials | ||||
Eheberg D1, Paulus G1, Dannemann S1, Batscheider A1 | ||||
1 IMS Health GmbH & Co. OHG, Munich, Germany | ||||
ISPOR 18th Annual European Congress, 7-11 November 2015, Milan, Italy |
||||
, Poster | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2015 | English | , Pricing & Reimbursement | |
DOES CONDITIONAL MARKETING AUTHORISATION INFLUENCE MARKET ACCESS IN FRANCE, ENGLAND, AND GERMANY? | ||||
Kaaniche A1, Troubat A1, Sherwood A2 | ||||
1IMS, PARIS, France, 2IMS Health, La Défense, France | ||||
ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
, Abstract, Poster | ||||
, France, Germany, UK | ||||
Condition | Year | Language | Analysis type | |
, Health policy, Pricing and reimbursement | 2015 | English | , Market impact | |
Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. | ||||
Detournay B1, Halimi S2, Robert J1, Deschaseaux C3, Dejager S4. | ||||
1Cemka-Eval, Bourg-la Reine, France. 2Department of Diabetology, Endocrinology and Nutrition, Grenoble University Hospital Center, Grenoble, France ; University Joseph Fourier, Grenoble, France. 3Novartis Pharma SAS, Market Access Department, Rueil-Malmaison, France. 4Novartis Pharma SAS, Medical and Scientific Affairs, Rueil Malmaison, France ; Department of Diabetology, Metabolism and Endocrinology, Pitié-Salpétrière Hospital, Paris, France. | ||||
Vasc Health Risk Manag. 2015 Jul 17;11:417-25. doi: 10.2147/VHRM.S84507. eCollection 2015. |
||||
, Article | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Pricing and reimbursement | 2015 | English | , Prospective study, Retrospective database analysis | |
First experiences with the new testing examination and treatment methods in Germany: Is this a new AMNOG clone? | ||||
Bonduelle D1, Eheberg D1, Plantoer S1 | ||||
1 IMS Health, Munich, Germany | ||||
ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
, Poster | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2014 | English | , Pricing & Reimbursement | |
Quality of life-a rarely acknowledged key category within the AMNOG process in Germany | ||||
Eheberg D., Shlaen R., Batscheider A., Gohlke A. | ||||
IMS Health, Munich, Germany | ||||
VALUE IN HEALTH 17 (2014) A323–A686 |
||||
, Abstract, Poster | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2014 | English | , Quality of life | |
HTA, budget impact tools and international price referencing from China’s perspective: what are the current developments and future considerations? | ||||
Koh L1, Li SC2, Zhang M3, Glaetzer C1 | ||||
1 Johnson & Johnson, Singapore, Singapore 2 School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, Australia 3 IMS Consulting, Shanghai, China | ||||
ISPOR 6th Asia-Pacific Conference, Beijing, China, 6-9 September, 2014 |
||||
, Panel presentation | ||||
, China | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2014 | English | , Pricing & Reimbursement | |
Payment by use: Achieving a new value paradigm for oncology | ||||
Woolmore A, Simpson D | ||||
RWE Solutions, IMS Health, London, UK | ||||
AccessPoint, 2014, May; 4(8): 26-31 |
||||
, Article | ||||
Abstract: http://issuu.com/ims_heor_publications/docs/ims_rwe_accesspoint_8_-_250514f_iss | ||||
Condition | Year | Language | Analysis type | |
, Oncology, Pricing and reimbursement | 2014 | English | , Real World Evidence | |
High-value oncology targeted therapies: Opportunities and challenges in emerging Asia Pacific markets | ||||
Afable A, Caputo J | ||||
IMS Health, Asia-Pac, Singapore, Singapore | ||||
AccessPoint, 2014, May; 4(8): 46-50 |
||||
, Article | ||||
, Asia Pacific | ||||
Abstract: http://issuu.com/ims_heor_publications/docs/ims_rwe_accesspoint_8_-_250514f_iss | ||||
Condition | Year | Language | Analysis type | |
, Oncology, Pricing and reimbursement | 2014 | English | , Real World Evidence | |
Trends in time to market access in Europe - is it getting better? | ||||
Flostrand SJ1, Lor S1, Anon Y2 | ||||
1IMS Consulting Group, La Défense Cedex, France, 2IMS Health, La Défense Cedex, France | ||||
ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
, Poster | ||||
Condition | Year | Language | Analysis type | |
, Health policy, Pricing and reimbursement | 2014 | English | , Market impact | |
Reimbursement Patterns for Enbrel® (etanercept) As Senior Patients Transition From Private to Public Drug Plan Insurance | ||||
Garces K1 , Poulin-Costello M1, Millson B2 | ||||
1 Amgen Canada, Mississauga, ON, Canada 2 IMS Health Canada Inc, Kirkland, QC, Canada | ||||
CAPT 2014 |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/amgencapt-poster-print.pdf | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2014 | English | , Retrospective cohort analysis | |
Comparison of drug assessments in France, Germany and UK: is European HTA a reality? | ||||
Perrin l1, Troubat A1 | ||||
1. IMS Health, La Défense, France | ||||
ISPOR 16th Annual European Congress - Nov2013 |
||||
, Poster | ||||
, France, Germany, UK | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2013 | English | , Pricing & Reimbursement | |
A price comparison study of recent drugs in EU5, 2008-2012 | ||||
1. Le Pen C, 2. Vigier D, 2. Grandfils N | ||||
1. Université Paris Dauphine, Paris France . 2. IMS Health, Paris La Défense France | ||||
16th annual European ISPOR |
||||
, Abstract | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2013 | English | , Pricing & Reimbursement | |
Impact de la baisse du taux de remboursement des anti-arthrosiques symptomatiques d’action lente (AASALs) sur la prescription des AINS par les médecins généralistes français | ||||
P Hilliquin (1); S Bouée (2); I Dardour (3); A Letierce (4); V Leblanc (3); - (1) Corbeil-Essonnes - France; (2) Bourg-la-Reine - France; (3) Courbevoie - France; (4) Boulogne-Billancourt - France | ||||
26ème congrès français de Rhumatologie |
||||
, Poster | ||||
, France | ||||
Abstract: http://poster.rhumatologie.asso.fr/ | ||||
Condition | Year | Language | Analysis type | |
, Pain, Pricing and reimbursement, Rheumatology | 2013 | French | , Retrospective database analysis | |
Accessibility of Orphan Drugs in France, United Kingdom and Germany: Different Approaches with Regard to HTA and Prices | ||||
N. Grandfils, H. Hounkanlin, A. Troubat | ||||
IMS Health, PARIS LA DEFENSE, France | ||||
ISPOR 16th - Dublin 02-03 Novembre 2013 |
||||
, Poster | ||||
, France, Germany, UK | ||||
Abstract: http://www.ispor.org/ | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2013 | English | ||
A Cost-Utility Analysis of Ranibizumab in Age-Related Macular Degeneration Based on Real-Life Observational Data in France | ||||
De Pouvourville G1 ; Lafuma A2 ; Moeremans K3 ; Nivelle E3 ; Umuhire D4 ; Gerlier L3 ; Maurel F5 ; Ponthieux A6. | ||||
1ESSEC Chair of Health Systems, Cergy, France ; 2Cemka Eval, Bourg La Reine, France ; 3IMS Health HEOR, Vilvoorde, Belgium ; 4IMS Health, Paris La Défense, France ; 5IMS Health, Paris La Défense, France ; 6Novartis Pharma S.A.S., Rueil-Malmaison Cedex, France. | ||||
ISPOR 16th - 02/03 novembre 2013 Dublin |
||||
, Poster | ||||
, France | ||||
Abstract: www.ispor.org | ||||
Condition | Year | Language | Analysis type | |
, Ophthalmology, Pricing and reimbursement | 2013 | English | ||
Does Europe reward reformulations? A data driven analysis of value preservation through reformulation. | ||||
Hughes ALH1 ; Luft D1 ; Lions I2 ; Flostrand SJA3. | ||||
1IMS Consulting Group, London, United Kingdom ; 2IMS Consulting Group, Basel, Switzerland ; 3IMS Consulting Group, Paris La Défense, France. | ||||
ISPOR 16th 02/06 Novembre Dublin |
||||
, Poster | ||||
Abstract: www.ispor.org | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2013 | English | ||
Variability in hybrid drug availability and pricing in europe. | ||||
Flostrand SJA1, Lor S1, Hughes ALH2 | ||||
1IMS Consulting Group, La Défense, Paris, France, 2IMS Consulting Group, London, United Kingdom | ||||
ISPOR 16th 02/06 Novembre 2013 Dublin |
||||
, Abstract | ||||
Abstract: www.ispor.org | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2013 | English | ||
The sharp decrease of drug's access to reimbursement in France in 2011 | ||||
Hounkanlin H, Troubat A, Morlet-Vigier D | ||||
IMS Health, Puteaux, France | ||||
15th European ISPOR in 2012 |
||||
, Abstract, Poster | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2012 | English | , Pricing & Reimbursement | |
Drug reimbursement maintenance : a French challenge in 2011 | ||||
Hounkanlin H, Troubat A, Morlet-Vigier D | ||||
Ims health, Puteaux, France | ||||
15th European Ispor in 2012 |
||||
, Abstract, Poster | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2012 | English | , Market impact | |
Impact of payer perceptions of pharma companies on access decisions - an analysis of unprompted expressions in payer interviews | ||||
Ruppert A, Petrie N, King Z, Plata A, Rao N | ||||
IMS Consulting Group, Cambridge, UK | ||||
ISPOR 15th Annual European Congress, 3-7 November 2012, Berlin, Germany |
||||
, Poster | ||||
Abstract: http://www.ispor.org/congresses/Berlin1112/Posters1.aspx | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2012 | English | , Market impact | |
Indirect identification of payer perceptions through retrospective analysis of interview write-ups | ||||
Ruppert A, King Z, Petrie N, Rao N, Plata A | ||||
IMS Consulting Group, Cambridge, UK | ||||
ISPOR 15th Annual European Congress, 3-7 November 2012, Berlin, Germany |
||||
, Poster | ||||
Abstract: http://www.ispor.org/congresses/Berlin1112/Posters4.aspx | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2012 | English | , Pricing & Reimbursement | |
Real World Evidence: Meeting the challenge of stakeholder needs for demonstrating value in Asia | ||||
Nelson M1, Ngorsuraches S2, Caputo J3 | ||||
1 IMS Health, Alexandria, US 2 Prince of Songkla University, Songkla, Thailand 3 IMS Health, Singapore | ||||
ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan, September 2nd – 4th 2012 |
||||
, Podium presentation | ||||
, Asia Pacific | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2012 | English | , Pricing & Reimbursement | |
Issues in adapting Global Health Economic Models to Emerging Markets: A conversation with Health Authorities, Pharmaceutical Industry and Consultants in Asia Pacific | ||||
Arnold RJG1, Xuan J2, Hu S3, Lee KKC4 | ||||
1 HEOR, IMS Health, New York, NY, USA 2 Pfizer, New York, NY, USA 3 Shanghai Bureau of Health, Fudan University, Shanghai, China 4 Monash University Sunway Campus, Bandar Sunway, Malaysia | ||||
ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan, September 2nd – 4th 2012 |
||||
, Workshop | ||||
Abstract: http://www.ispor.org/conferences/Taipei0912/workshops.asp | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2012 | English | , Workshop | |
Conducting Real-World Studies in emerging Asian markets | ||||
Lara N1, Caputo J2, Lai H-J3, Yin-Yin Huang G4 | ||||
1 IMS Health, Barcelona, Spain 2 IMS Health, Singapore, Singapore 3 Merck, Sharp & Dohme Corp., Taipei, Taiwan 4 IMS Health, Taipei, Taiwan | ||||
ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan, September 2nd – 4th 2012 |
||||
, Workshop | ||||
, Asia Pacific | ||||
Abstract: http://www.ispor.org/conferences/Taipei0912/workshops.asp | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2012 | English | , Workshop | |
Cost-Effectiveness Modeling in Cancer | ||||
Lamotte M1, Vandekerckhove S1 | ||||
1IMS Health, Brussels | ||||
AccessPoint, Nov 2012; Vol 3(5); 26- 29 |
||||
, Article | ||||
Abstract: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Services/Pharma%20Commercial%20Effectiveness/Health%20Economics%20_%20Outcomes%20Research/AccessPoint-5-281012%20F.pdf | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2012 | English | , Cost effectiveness | |
Cost-effectiveness of Tapentadol prolonged-release (PR) compared to oxycodone controlled release (CR) in patients with chronic severe non-cancer pain in Ireland | ||||
Obradovic M.1, Ikenberg R.2, Hertel N.3, Liedgens H.1 | ||||
1 Grünenthal GmbH, Aachen, Germany, 2 IMS Consulting Group, Nuremberg, Germany, 3 IMS Consulting Group, London, UK | ||||
ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain |
||||
, Poster | ||||
, Ireland | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2011 | English | , Cost effectiveness | |
Indications using real-world data in United States commercially-insured population | ||||
Schabert V1, Gandra SR2, Watson C2, Fox KM3, Yeaw J4, Goodman S4, Milev S5, Harrison DJ2 | ||||
1IMS Health, Falls Church, VA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 4IMS Health, Watertown, MA, USA, 5IMS Brogan, A unit of IMS, Ottawa, ON, Canada | ||||
ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain |
||||
, Poster | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2011 | English | , Economic evaluation | |
Market access barriers for Biosimilars in Spain and Germany: Epoetin Alfa Example | ||||
Hurtado P, Vieta A, Espinós B, Badia X | ||||
IMS Health, Barcelona, Spain | ||||
ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain |
||||
, Poster | ||||
, Germany, Spain | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2011 | English | , Market impact | |
Modeling cost-effectiveness of drug treatments for severe chronic non-cancer pain in Portugal | ||||
Obradovic M.1, Ikenberg R.2, Hertel N.3, Gouveia M.4, Liedgens H.1 | ||||
1 Grünenthal GmbH, Aachen, Germany, 2 IMS Consulting Group, Nuremberg, Germany, 3 IMS Consulting Group, London, UK, 4 Católica School of Business and Economics, Lisbon, Portugal | ||||
ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain |
||||
, Poster | ||||
, Portugal | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2011 | English | , Cost effectiveness | |
Optimizing strategic direction with systematic value development. | ||||
Joy K1, Lewis SJ2 | ||||
1 Health Economics and Outcomes Research, IMS Health, Falls Church, VA, USA 2 BCBS of Colorado/Nevada, Lafayette, CO, USA | ||||
ISPOR 15th Annual International Meeting, May 15-19, 2010, Atlanta, GA, USA |
||||
, Workshop | ||||
Abstract: http://www.ispor.org/meetings/atlanta0510/Workshops.asp#sessionI | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2010 | English | , | |
Developing global road maps for reimbursement processes used in health technology assessment: pharmaceuticals, medical devices, and diagnostics. | ||||
Sullivan N1, Szeinbach S2, Seoane-Vazquez E2, Matuszewski K3, Mayo K4, Holmstrom S5, Wilson G6, Chicoye A7 | ||||
1Technology Assessment Evaluation Group, LLC, Encinitas, CA, USA, 2Ohio State University, Columbus, OH, USA, 3Elsevier/Gold Standard, Tampa, FL, USA, 4Bridgehead International Consulting, Denville, NJ, USA, 5Astellas Pharma Europe, Leiderdorp, The Netherlands, 6GE Healthcare, Buckinghamshire, UK, 7IMS HEALTH, PUTEAUX CEDEX, France | ||||
ISPOR 15th Annual International Meeting, May 15-19, 2010, Atlanta, GA, USA |
||||
, Poster | ||||
Abstract: http://www.ispor.org/meetings/atlanta0510/Posters2.aspx | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2010 | English | , | |
Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions. | ||||
Hess G, Nordyke RJ, Hill J, Hulnick S. | ||||
1IMS Health (formally SDI Health), Plymouth Meeting, Pennsylvania, 2Leonard Davis Institute, University of Pennsylvania, Pennsylvania, 3Amgen Inc, Thousand Oaks, California | ||||
Am J Hematol. 2010 Nov;85(11):838-43. |
||||
, Article | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed?term=effects of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions&cmd=correctspelling | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2010 | English | ||
Desigualdades en la financiación de medicamentos entre comunidades autónomas en España [Inequalities in the financing of medicines among autonomous regions in Spain] | ||||
Vieta A, Badia X | ||||
Vieta A1, Badia X1 1Health Economics and Outcomes Research, IMS Health, Barcelona, Spain, | ||||
Medicina Clínica (Barc). 2009;132(9):364-368 |
||||
, Article | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2009 | Spanish | ||
Complex Attention-Deficit/Hyperactivity Disorder: Patient Characteristics, Health Care Utilization And Costs In A Retrospective Observational Claims Study | ||||
Hess G1, Sasane R2, Hill J1, Hodgkins P2, Shah MR1 | ||||
1IMS Health, former SDI Health, Plymouth Meeting, PA, USA, 2Shire Pharmaceuticals, Wayne, PA, USA | ||||
Value in Health Volume 12, Issue 7 , Page A361, October 2009 |
||||
, Article | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(10)74773-2 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Pediatrics, Pricing and reimbursement | 2009 | English | , Cost analysis, Cost utility, Observational study | |
Freie Arzneimittelpreise in Deutschland – eine Fiktion? Auswirkungen der Methode des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) zur Kosten-Nutzen-Bewertung auf die Preisbildung von Arzneimitteln [Free pricing for pharmaceuticals in Germany - a fiction? Effects of the method of the institute for quality and economic efficiency in health care for cost-utility-evaluation regarding the pricing of pharmaceuticals] | ||||
Pirk O1, Fricke F-U1 | ||||
1 IMS Health, Nuremberg, Germany | ||||
Pharm. Ind. 70(4): 452–456 |
||||
, Article | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2008 | German | , Pricing & Reimbursement | |
The comparison of different modelling techniques in cost effectiveness analysis: Using stroke care as an example. | ||||
Saka O1, Samyshkin Y3, McGuire A2, Wolfe CCDA1 | ||||
1 Division of Health and Social Care Research, King’s College, London, UK 2 London School of Economics and Political Science, LSE Health and Social Care, London, UK 3 IMS Health, London, UK. | ||||
7th European Conference on Health Economics Rome (Italy), 23-26 July 2008 - Faculty of Economics, University of Rome. |
||||
, Conference | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2008 | English | , Cost effectiveness | |
Developing key performance indicators for the Australian reimbursement system | ||||
Abela M, Davey P, Carroll J, Brown B, Yates R | ||||
ISPOR 10th Annual Meeting |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2008 | English | , Pricing & Reimbursement | |
Preisbildung und Erstattung [Pricing and reimbursement] | ||||
Pirk O | ||||
IMS Health, Nuremberg, Germany | ||||
Schöffski O, Fricke F-U, Guminski W (ed.). Pharmabetriebslehre, Berlin-Heidelberg, Springer, 2008, 155-172 |
||||
, Book chapter | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2008 | German | , Methodology | |
More Policy Initiatives in the Australian National Reimbursement System That Will Reduce Costs Dramatically | ||||
Davey PJ, Abela MJ and Aristides M. | ||||
ISPOR Ninth Annual International Meeting, Arlington, VA. May 16-19, 2004. |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2007 | English | ||
Inequalities in the financing of drugs among autonomous regions in Spain | ||||
Badia X1, Vieta A1 | ||||
1Health Economics and Outcomes Research, IMS Health, Barcelona, Spain, | ||||
ISPOR 11th Annual European Congress 2008 November 8-11, Athens, Greece |
||||
, Poster | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2007 | English | ||
Outcomes Research and Pharmaceutical Pricing. | ||||
Tierce JC. | ||||
42nd Annual DIA Meeting, Philadelphia, PA, June 2006. |
||||
, Abstract | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2006 | English | ||
Medicare Part D Reimbursement Hotlines: Just What the Doctor Ordered. | ||||
Braun L, DeKoven MP, De Masi C, Maltz J, Ross H. | ||||
Product Management Today. 2006 September; 17(9): 34-36, 38-39 |
||||
, Manuscript in preparation | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2006 | English | ||
Ensuring Access for Specialty Pharmaceuticals through Payer Education. | ||||
Dekoven MP, Marlo K, Robinson S. | ||||
Specialty Pharma. 2006 Jan/Feb; 2(1): 62-65. |
||||
, Manuscript in preparation | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2006 | English | ||
Impact of an inspector's stamp approval policy into the atypical antipsychotic market in andalusia (Spain) | ||||
Badia X, Vieta A, Lara N, Giménez E | ||||
ISPOR 2007 10th Annual European Congress |
||||
, Abstract | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2006 | English | ||
Pricing reimbursement and health outcomes | ||||
Davey P | ||||
Regional Conference in Cost-effective Healthcare 2006 |
||||
, Invited speaker | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2006 | English | , Pricing & Reimbursement | |